AZ On The Rise In All Regions And Therapy Areas
Executive Summary
The drug major's Q2 sales soared past consensus forecasts, driven by its three soon-to-be oncology blockbusters – Tagrisso, Imfinzi and Lynparza.
You may also be interested in...
AZ Pushes Further Ahead In PARP Race With Lynparza/Avastin Combo
The PAOLA-1 study has shown the benefit of Lynparza for ovarian cancer patients regardless of tumor mutation status which should firm up the drug's dominance in the PARP inhibitor space.
GSK's Zejula Poised To Take On Lynparza In First-Line Ovarian Cancer
The Phase III PRIMA study in first-line ovarian cancer was positive for progression-free survival in patients regardless of their biomarker status, GSK reported.
AstraZeneca, FibroGen Plan New Roxadustat Filings, But CV Data Confuse Investors
Confusion over top-line pooled cardiovascular Phase III safety data on anemia therapy roxadustat caused shares in AstraZeneca and FibroGen to slide on 9 May, but analysts later said the negative reaction was overdone.